NEW YORK, July 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP ("XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP" or the "Company") (NYSE: XIFR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP investors who were adversely affected by alleged securities fraud between September 27, 2023 and January 27, 2025. F ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - A class action securities lawsuit has been filed against Petco Health and Wellness Company, Inc. for alleged securities fraud affecting investors between January 14, 2021, and June 5, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Petco's pandemic-related business advantages were not sustainable and that its business model focused on premium pet food was flawed [2] - It is alleged that the strength of Petco's differentiated product strategy was overstated, and the true scope of the issues was downplayed by the defendants [2] - Defendants are accused of overstating Petco's ability to achieve sustainable, profitable growth, leading to materially false and misleading public statements [2] Group 2: Next Steps for Investors - Investors who suffered losses in Petco during the specified timeframe have until August 29, 2025, to request to be appointed as lead plaintiff, although participation does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, following allegations of overstating cost savings and revenue projections related to transition services agreements after its spin-off from Labcorp [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, specifically titled Deslande v. Fortrea Holdings Inc., et al., No. 1:25-cv-04630 [2]. - Investors have until August 1, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Fortrea is a global contract research organization that provides biopharmaceutical product and medical device development solutions, having been spun off from Labcorp in June 2023 [3]. Group 3: Allegations and Financial Impact - Allegations state that Fortrea exaggerated the cost savings and margin improvements expected from exiting transition services agreements, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as claimed, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full-year 2024 results, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about RP-A501's safety while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - Petco Health and Wellness Company, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between January 14, 2021, and June 5, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Petco's pandemic-related business advantages were not sustainable and that its business model, which focuses on premium pet food, was overstated [2] - Defendants allegedly downplayed the severity of issues affecting Petco's business and the necessary changes to address these issues, leading to an overstatement of the company's ability to achieve sustainable growth [2] - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 29, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - The founder of HYBE, Bang Si-hyuk, is facing a criminal investigation by South Korean prosecutors for allegedly deceiving investors prior to the company's IPO in 2020 [1][5]. Group 1: Background and Company Overview - HYBE is the highest-valued entertainment company in South Korea, with a market capitalization of 11.1 trillion KRW (approximately 57.2 billion RMB), surpassing the combined value of the other three major entertainment companies in Korea by 4 trillion KRW [4]. - The case has garnered significant attention due to the scale of the alleged securities fraud [5]. Group 2: Allegations and Financial Implications - Bang Si-hyuk is accused of misleading investors, including venture capital firms, in 2019 by suggesting that HYBE had no plans for an IPO, which led them to sell shares to a special purpose company set up by HYBE executives [5][6]. - While investors sold their shares, HYBE was preparing for its IPO, and the special purpose company later sold its shares, allowing Bang Si-hyuk to earn approximately 190 billion KRW (around 980 million RMB) from the transaction [6]. - The agreement regarding profit-sharing was not disclosed during the IPO process, which constitutes a violation of disclosure regulations [6]. Group 3: Legal Consequences and Regulatory Response - According to Article 443 of the Capital Markets Act in South Korea, if illegal gains exceed 5 billion KRW (approximately 26 million RMB), the offender could face at least 5 years in prison, with the possibility of life imprisonment for higher amounts [7]. - The South Korean financial regulatory agency has stated its intention to cooperate fully with the prosecutor's investigation and to thoroughly examine the allegations [7]. - HYBE expressed regret over the financial regulator's decision and stated its commitment to clarifying the situation during the upcoming investigation to restore trust among stakeholders [7].

Company Overview - Encompass Health Corporation is the largest owner and operator of inpatient rehabilitation hospitals in the United States [3] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Encompass Health, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1] - The investigation is open to information from investors who may have suffered losses related to Encompass Health [2] Recent Revelations - A New York Times article published on July 15, 2025, reported that Encompass Health accounts for about one in seven rehab facilities nationally, owning 34 of the 41 inpatient rehab facilities rated by Medicare as having statistically significantly worse rates of potentially preventable readmissions for discharged patients [4] - The article also noted that Encompass Health owned 28 of the 87 rehab facilities, with 65 being for-profit, that had worse rates of potentially preventable readmissions to general hospitals during patient stays [4] - Following the publication of this article, Encompass Health's stock price fell by more than 10% [4]

Core Viewpoint - A class action securities lawsuit has been filed against iRobot Corporation, alleging securities fraud that affected investors between January 29, 2024, and March 11, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that iRobot overstated the effectiveness of its restructuring plan following the termination of the Amazon acquisition, leading to doubts about its ability to operate profitably as a standalone company [2]. - It is alleged that the company's public statements were materially false and misleading, raising concerns about its ability to continue as a going concern [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until September 5, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its expertise in complex securities litigation [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [4].